Hemofilia adquirida A y B como manifestación inicial de linfoma no Hodgkin. Reporte de un caso y revisión de la literatura

  • Bonell Patiño Servicio de Hematología, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
  • Paola Omaña Servicio de Medicina Interna – Hematología, Hospital Universitario Clínica San Rafael (HUCSR), Bogotá, D. C., Colombia
  • Diana Otero Servicio de Hematología, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
  • July Montoya Departamento de Anestesia y reanimación, Hospital Universitario Clínica San Rafael (HUCSR), Bogotá, D. C., Colombia
Palabras clave: Hemofilia adquirida, Hemofilia A, Hemofilia B, Linfoma

Resumen

La hemofilia adquirida es una complicación rara y potencialmente fatal en pacientes con neoplasias hematológicas (desórdenes linfoproliferativos) o tumores sólidos. Presentamos una paciente de 75 años de sexo femenino con antecedente de hipertensión arterial y anemia ferropénica que ingresa a urgencias por cuadro de dolor abdominal generalizado tipo cólico, asociado a episodios eméticos de contenido alimentario y deposiciones melénicas. Dentro de los estudios iniciales se encontraron: tiempos de coagulación prolongados, prueba de mezclas de aPTT con evidencia de anticoagulante circulante específico, factor IX, 0% y factor VIII, 0% con inhibidores de factor VIII y IX en 180 UB y 130 UB respectivamente. Se consideró que la paciente cursaba con hemofilia adquirida A y B con realización de estudios de extensión diagnosticándose linfoma no Hodgkin marginal esplénico.

Referencias

Giangrande P. Acquired Hemophilia. Revised edition. World Federation of Hemophilia. 2012;(38) [internet]. Available in: http://www1.wfh.org/publications/files/pdf-1186.pdf

Knoebl P, Marco P, Baudo F, Collins P, Hüth-Kuhne A, Nemes L, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10(4):622-31.

Seethala S, Collins NP Jr, Comerci G Jr. An Unusual Etiology for Elevation of Activated Partial Thromboplastin Time (aPTT) in SLE: Acquired Hemophilia and Lupus Anticoagulant. Case Rep Hematol. 2013;2013:521785.

Hay CR. Acquired haemophilia. Baillière’s Clin Haematol. 1998;11(2):287-303.

Reeves BN, Key NS. Acquired hemophilia in malignancy. Thromb Res. 2012;129 Suppl 1:S66-8.

Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemos. 1981;45(3):200-3.

Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemos. 1997;78(6):1463-7.

Yee TT, Taher A, Pasi KJ, Lee CA. A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period. Clin Lab Haematol. 2000;22(5):275-8.

Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Bri J Haemotol. 2003;121(1):21-35.

Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood. 2007; 109(5):1870-7.

Bitting RL, Bent S, Li Y, Kohlwes J. The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis. Blood Coagul Fibrinolysis. 2009;20(7):517-23.

Seethala S, Barnes K, Corral J. Acquired factor VIII inhibitor: a rare etiology for bruisability and anemia. Indian J Hematol Blood Transfus. 2013;29(3):178-80.

Kamal A, Tefleri A, Pruthi, R. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc. 2007;82(7):864-73.

Remotti L, Grosso SH, Ingratti MF, Vera MP, Woods A, Sánchez-Luceros A, et al. Inhibidores adquiridos de la coagulación: enfoque diagnóstico y casos especiales. Acta Bioquím Clin Latinoam. 2016;50(2):291-301.

Rosner E, Pauzner R, Lusky A, Modan M, Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemost. 1987; 57(2):144-7.

Tcherniantchouk O, Laposata M, Marques MB. The isolated prolonged PTT. Am J Hematol. 2013;88(1):82-5.

Oh J, Lim Y, Jang MJ, Huh JY, Shima M, Oh D. Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A. Blood Res. 2013;48(1):58-62.

Jedidi I, Hdiji S, Ajmi N, Makni F, Masmoudi S, Elloumi M, et al. Acquired haemophilia B: a case report and literature review. Ann Biol Clin (Paris). 2011;69(6):685-8.

Miller K, Neely JE, Krivit W, Edson JR. Spontaneously acquired factor IX inhibitor in a nonhemophiliac child. J Pediatr. 1978;93(2):232-4.

Mazzucconi MG, Peraino M, Bizzoni L, Bernasconi S, Luciani M, Rossi GD. Acquired inhibitor against factor IX in a child: successful treatment with high-dose immunoglobulin and dexamethasone. Haemophilia. 1999;5(2):132-4.

Largo R, Sigg P, von Felten A, Straub PW. Acquired factor-IX inhibitor in a nonhaemophilic patient with autoimmune disease. Br J Haematol. 1974;26(1):129-40.

Berman BW, McIntosh S, Clyne LP, Goldberg B, Lobel J, Komp DM. Spontaneously acquired Factor IX inhibitors in childhood. Am J Pediatr Hematol Oncol. 1981;3(1):77-81.

Collins PW. Therapeutic challenges in acquired factor VIII deficiency. Hematology Am Soc Hematol Educ Program. 2012;2012:369-74.

Lian EC, Villar MJ, Noy LI, Ruiz-Dayao Z. Acquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and prednisone. Am J Hematol. 2002;69(4):294-5.

Zeitler H, Ulrich-Merzenich G, Panek D, Goldmann G, Vidovic N, Brackmann HH, et al. Extracorporeal treatment for the acute and long-term outcome of patients with life-threatening acquired hemophilia. Transfus Med Hemother. 2012;39(4):264-70.

Kasper C. Diagnosis and Management of Inhibitors to Factors VIII and IX. An Introductory Discussion for Physicians. Treatment of Hemophilia: World Federation of Hemophilia, 2004.

Publicado
2019-09-29
Sección
Reportes de caso